Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT

Clin Nucl Med. 2015 Feb;40(2):e163-6. doi: 10.1097/RLU.0000000000000594.

Abstract

Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68(HBED-CC)], abbreviated as Ga-PSMA, is a novel radiotracer undergoing evaluation for PET/CT imaging of prostate carcinoma. Its major advantage is the sensitive detection of lesions even at low prostate-specific antigen level and high target-to-background ratios obtained in metastatic lesions, which is better than that obtained with F-fluoromethylcholine. We present the case of a 28-year-old man with poorly differentiated prostate carcinoma with neuroendocrine differentiation, whose lesions did not show significant Ga-PSMA localization. As literature on utility of Ga-PSMA PET/CT for imaging prostate carcinoma grows, it is important to be aware of potential false negatives that could influence study results.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Carcinoma / diagnostic imaging*
  • Carcinoma / pathology
  • Edetic Acid / analogs & derivatives*
  • Humans
  • Male
  • Multimodal Imaging
  • Neuroendocrine Tumors / diagnostic imaging*
  • Neuroendocrine Tumors / pathology
  • Oligopeptides*
  • Positron-Emission Tomography*
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / pathology
  • Radiopharmaceuticals*
  • Tomography, X-Ray Computed*

Substances

  • Oligopeptides
  • Radiopharmaceuticals
  • Edetic Acid
  • Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))